The following abstracts showcase the top cutting-edge research presented at the European Society for Medical Oncology (ESMO) ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Visit us on Facebook. Opens in a new tab or window Visit us ...

Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds ...

Now, new data from the POD1UM-303 study reported at ESMO suggests the company could resurrect the SCAC indication and move Zynyz into the first-line setting to boot. Given in combination with ...

The favorable initial data highlights EO-3021's unique potential ... Additionally, we look forward to sharing preclinical data at ESMO-IO 2024 in December that further reinforce our combination ...

and the European Society for Medical Oncology (“ESMO”) Asia Congress 2024, taking place on December 6-8, 2024 in Singapore. Long-term safety and efficacy data from a follow-on, open-label sub ...

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with ...